Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1463 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Sergei Noskov und 13 weiteren Autor:innen. Beteiligte Einrichtung: City Hospital No. 3, Yaroslavl, Russia. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Cross-Over Studies, Benzimidazoles, Drugs, Generic. Die Arbeit nennt 12 Literaturangaben. Gefördert von: GEROPHARM, Russia.
Abstract (Originalsprache)
This was an open‐label, randomized, single‐dose, 2‐period, crossover clinical trial with an adaptive design to evaluate the bioequivalence and comparative pharmacokinetics of generic glecaprevir/pibrentasvir versus the brand name product in healthy White male and female volunteers under fed conditions. Safety profiles were also assessed. A total of 56 healthy adult volunteers were enrolled and randomly assigned in a 1:1 ratio to receive a single dose of either the generic or reference formulation. After a 7‐day washout period, subjects received the alternate product. Blood samples were collected at pre‐specified time points up to 48 hours post‐dosing. Plasma concentrations of glecaprevir and pibrentasvir were determined using a validated high‐performance liquid chromatography‐tandem mass spectrometry method. The geometric mean ratios of the test to the reference formulation for maximum plasma concentration (C max ) and area under the concentration‐time curve from drug administration to the last measurable concentration (AUC 0‐t ) fell within the predefined bioequivalence range of 80%‐125%. Both formulations demonstrated comparable pharmacokinetic profiles for glecaprevir and pibrentasvir, and can be considered bioequivalent. No adverse events were reported, and both formulations were well tolerated by all participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- City Hospital No. 3, Yaroslavl, Russia.
- R&D Center, GEROPHARM, Saint-Petersburg, Russia.
- LLC "Center for Pharmaceutical Analytics", Moscow, Russia.
Förderung
- GEROPHARM, Russia
Zitieren
APA
Noskov, S., Parulya, O., Lutskova, L., Arefeva, A., Protsenko, E., Banko, V., Radaeva, K., Matvienko, I., Gefen, M., Karnakova, P., Knyazeva, A., Komarov, T., Archakova, O., & Shohin, I. (2024). Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1463
Vancouver
Noskov S, Parulya O, Lutskova L, Arefeva A, Protsenko E, Banko V, et al. Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1463
BibTeX
@article{Noskov2024,
author = {Noskov, Sergei and Parulya, Olesya and Lutskova, Lyudmila and Arefeva, Anna and Protsenko, Ekaterina and Banko, Veniamin and Radaeva, Kseniia and Matvienko, Iuliia and Gefen, Maria and Karnakova, Polina and Knyazeva, Alina and Komarov, Timofey and Archakova, Olga and Shohin, Igor},
title = {Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1463}
}
EUVIMED